Summary
Amgen Inc. reported third-quarter 2019 results with total revenues of $5.74 billion, a decrease of 3% year-over-year, primarily due to lower other revenues. Net income rose 6% to $1.97 billion, and diluted Earnings Per Share (EPS) increased by 14% to $3.27. For the first nine months of 2019, total revenues decreased by 2% to $17.17 billion, while net income declined 5% to $6.14 billion, and diluted EPS increased by 4% to $10.01. The company announced a significant development with an agreement to acquire worldwide rights to Otezla® for $13.4 billion, expected to close by year-end 2019, which is intended to expand its inflammation portfolio. The report also highlighted ongoing legal proceedings related to patent disputes and biosimilar competition, which could materially impact financial results. Amgen continued its capital return program, repurchasing $6.6 billion of its stock in the first nine months and declaring quarterly dividends.
Financial Highlights
54 data points| Revenue | $5.74B |
| Cost of Revenue | $1.04B |
| Gross Profit | $4.43B |
| SG&A Expenses | $1.22B |
| Operating Expenses | $3.26B |
| Operating Income | $2.48B |
| Interest Expense | $313.00M |
| Net Income | $1.97B |
| EPS (Basic) | $3.29 |
| EPS (Diluted) | $3.27 |
| Shares Outstanding (Basic) | 599.00M |
| Shares Outstanding (Diluted) | 602.00M |
Key Highlights
- 1Total revenues for Q3 2019 decreased 3% to $5.74 billion, primarily due to a 30% drop in other revenues. Nine-month revenues were down 2% to $17.17 billion.
- 2Net income for Q3 2019 increased 6% to $1.97 billion, with diluted EPS rising 14% to $3.27. For the nine-month period, net income decreased 5% to $6.14 billion, while diluted EPS grew 4% to $10.01.
- 3Amgen entered into an agreement to acquire worldwide rights to Otezla® from Celgene for $13.4 billion, a significant strategic move expected to close by year-end 2019.
- 4Product sales saw a 1% decline year-over-year for both the quarter and the nine-month period. Key product ENBREL sales increased 6% in the quarter, while Neulasta® sales dropped 32% due to biosimilar competition.
- 5The company continued robust share repurchase activity, buying back $6.6 billion in the first nine months of 2019, and increased its authorized repurchase program by an additional $5.0 billion.
- 6Operating expenses decreased by 9% in the quarter and 1% year-to-date, partly due to a favorable year-over-year comparison related to an impairment charge in Q3 2018 and increased R&D spending year-to-date.
- 7Amgen faces ongoing legal proceedings and patent disputes related to several key products, including Sensipar® and ENBREL, which could materially impact future financial performance.